Trials / Completed
CompletedNCT01857232
Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy
Randomised, Double-blind, Dose-finding Phase II Study to Assess the Efficacy of APD403 in the Prevention of Nausea and Vomiting Caused by Cisplatin- or Anthracycline/Cyclophosphamide (AC)-Based Chemotherapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 342 (actual)
- Sponsor
- Acacia Pharma Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Comparison of efficacy of APD403 at preventing delayed sickness in patients who have received cancer chemotherapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ondansetron | 5HT3-antagonist |
| DRUG | Placebo | Comparator |
| DRUG | Dexamethasone | Corticosteroid |
| DRUG | Fosaprepitant | NK1 antagonist |
| DRUG | APD403 IV | Amisulpride IV 20 mg |
| DRUG | APD403 oral | Amisulpride oral 10, 20 or 40 mg |
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2015-02-01
- Completion
- 2015-02-01
- First posted
- 2013-05-20
- Last updated
- 2020-11-25
- Results posted
- 2019-03-12
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT01857232. Inclusion in this directory is not an endorsement.